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ABSTRACT:
Introduction: The potential for coordinated, multidisciplinary
telehealth to help connect people with Parkinson disease (PD) in
rural areas to PD specialists is crucial in optimizing care. Therefore,

and medication adherence.
Results: Average attendance was greater than 85% for all
participants. There were no serious adverse events and only nine

this study aimed to test the feasibility, safety, and signal of efficacy
of a coordinated telehealth program, consisting of speech therapy,
physiotherapy, and pharmaceutical care, for people with PD living
in some rural US communities.

minor events during treatment sessions (0.9% of all treatment
sessions had a participant report of an adverse event); all nine
cases resolved without medical attention. Although 14 of 16
outcomes had effect sizes trending in the direction of

Methods: Fifteen individuals with PD living in rural Wyoming and
Nevada, USA, participated in this single-cohort, 8-week pilot study.
Participants were assessed before and after 8 weeks of
coordinated, one-on-one telehealth using the following outcomes:

improvement, only two were statistically significant using nonparametric analyses: 30 second Sit-to-Stand (pre-test median=11.0
(interquartile range (IQR)=6.0); post-test median=12.0 (IQR=3.0)
and acoustic data work (pre-test median=756.0 dB s (IQR=198.4);

(1) feasibility: session attendance and withdrawal rate; (2) safety:

post-test median=876.3 dB s (IQR=455.5), p<0.05.

adverse events; and (3) signal of efficacy: Communication
Effectiveness Survey, acoustic data (intensity, duration, work
(intensity times duration)), Parkinson’s Fatigue Scale, 30 second Sit-

Conclusion: A coordinated, multidisciplinary telehealth program
was safe and feasible for people in rural communities who have
PD. This telehealth program also yielded a signal of efficacy for

to-Stand test, Parkinson’s Disease Questionnaire – 39, Movement

most of the outcomes measured in the study.

Disorder Society Unified Parkinson’s Disease Rating Scale – Part III,

Keywords:

exercise, management, physiotherapy, speech and communication disorder, medication, telerehabilitation, USA.

FULL ARTICLE:
Introduction
Parkinson disease (PD) is a complex neurodegenerative disease
that requires ongoing and increasingly more complex health care
as the disease progresses. Moreover, the required health care is
specialized and requires a team of PD healthcare specialists to
provide optimum care1-3. Bloem et al report that PD healthcare
specialists are more likely to adhere to PD treatment guidelines
than professionals with generic training and are more aware of the
role that other healthcare specialists offer for people with PD3. This
highlights the importance and necessity of specialist care for
people with PD. Although the management of PD is optimized by
a specialized team of healthcare providers, for most people with
PD, even in large urban areas, their care is often fragmented with
poor interdisciplinary collaboration and a lack of resources and
access3.
For people with PD who live in rural areas, these problems are
exacerbated because few PD specialists live and practice in rural
areas. Work by Singh et al supports this assertation in a qualitative
study on people with PD living in rural Wyoming4. The group
found that people with PD have significant challenges in accessing
information about PD, gaining access to PD healthcare specialists,
and accessing community support for their condition4. Because
people with PD in rural areas lack access, they often have a difficult
choice to make by either traveling long distances to see PD
specialists, choosing local generalists to manage their condition, or

forgoing PD specialized care altogether. Clearly, these choices are
not ideal when managing a complex and chronic condition like PD,
and delays in access can prolong or exacerbate health-related
problems, which in turn can lead to suboptimal care. Without
ongoing, coordinated services from specialists, people with PD in
rural areas are at a distinct disadvantage to their counterparts in
large, urban cities, who have access to many specialists with
expertise in PD. Therefore, increasing access for those in rural areas
is important in alleviating the disease burden for those with PD
and their caregivers.
One solution to the health disparities perpetuated by inadequate
healthcare access for people with PD living in rural areas is
telehealth. The growth of telehealth has been expedited by the
recent pandemic5-9, but there is still a need to build evidence for
the feasibility, safety, and efficacy of telehealth for people with
PD10,11. Several researchers have reported aspects of feasibility
and safety of telehealth for people with PD12-16. For those with PD
who live in underresourced areas or are homebound due to their
advancing PD, telehealth increases access to specialized care17.
Bush et al reported that people with PD living in rural Wyoming
were interested in pursuing advanced technology options to
address the barriers to their health care18. Studies have also
suggested that telehealth decreases the cost and travel burden for
people with PD19-21. Additional, telehealth can be used as a tool to
minimize patient exposure to contagious pathogens22 and this is

especially important in vulnerable populations like those with PD.
While these studies support a growing foundation of evidence, all
of the aforementioned studies were centered on ‘telemedicine’

This was a pilot, prospective cohort, phase II study on the
implementation of a coordinated, 8-week telehealth program,
consisting of speech therapy, physiotherapy, and pharmaceutical

rather than on a more collaborative, multidisciplinary care plan
involving other important members of the PD healthcare team as
cited in Bloem et al3. People with PD also cite a lack of care
coordination as a healthcare barrier for those in rural

care, using a single cohort of people with PD living in rural
Wyoming and Nevada, USA. Participants were assessed in the ‘on’
PD medication state before and after the 8-week telehealth
program as well as a 6-month follow-up assessment. The study

communities4. Therefore, there is a need to provide foundational
evidence for a multidisciplinary healthcare team approach for
telehealth for people with PD in rural communities. Moreover, this
approach might support the Triple Aim Initiative by the Institute
for Healthcare Improvement. They recommended that the US

was coordinated by a PD nurse and also an assistant study
coordinator who helped with scheduling and technology.
Participants

healthcare system may be improved by improving the patient care
experience, improving population health, and reducing healthcare
costs23.

The inclusion criteria were the following: English speaking,
diagnosed with idiopathic PD, taking at least one PD medication,
Hoehn and Yahr stages 1–4, aged 30 years or older, commitment
to attend scheduled sessions, access to internet to participate in

This study aimed to provide evidence for the feasibility, safety, and
signal of efficacy of a coordinated, multidisciplinary telehealth
program consisting of evidence-based speech therapy24-26,

telehealth sessions, and allowing communication to primary care
provider. The exclusion criteria were the following: dementia or
inability to follow directions; skilled nursing resident; comorbidities
that would preclude exercise participation or increase participant

physiotherapy27-31, and medication management/pharmaceutical
care32-34. The first aim was to test the feasibility of this
coordinated telehealth program over an 8-week period. For this
aim, it was hypothesized that the withdrawal rate would be less
than 12% and that 80% of participants would attend 80% of their
schedule treatment sessions for each of the three treatments in the
35

telehealth program over the 8-week study period . The second
aim was to assess the safety of the coordinated telehealth speech
therapy, exercise therapy, and pharmaceutical care. For this aim, it

risk (severe osteoarthritis/pain, stroke, severe respiratory problems,
traumatic brain injury, neuromuscular disease, atrial fibrillation,
poorly controlled cardiovascular disease, limb amputation,
osteoporosis, orthostatic or postural hypotension); a recent fall
that required physician evaluation (emergency department, urgent
care, hospitalization) within the past year; use of an assistive device
(or person) for walking, standing, or balance; and current use of a
structured exercise regimen defined as participation in a regular

was hypothesized that there would be no major adverse events,
including falls, cardiac events, and injuries, over the course of the

exercise program consisting of more than 60 minutes per week in
total.

8-week telehealth program. The third aim was to detect a signal of
efficacy of the coordinated telehealth program across several

Participants were recruited from rural areas in Wyoming and

domains of outcomes, including communication effectiveness,
physical performance measures, medication adherence, and
disease-specific mobility and quality-of-life measures. Identifying a
signal of efficacy is important for determining the direction and
design of future research on this telehealth program.
Methods
Design overview

Nevada as a sample of convenience using snowball recruitment
strategies and public media from November 2017 to December
2018. Of the 17 individuals who were formally screened,
15 matriculated into the study and all 15 completed the 8-week
outcomes (Fig1). Fifteen individuals with PD participated (mean
age 73.3 (range 57–93) years; 7 males, 8 females; mean disease
duration 9.3 (range 1–22) years) (Table 1). All participants noted
some technology experience prior to this telehealth study, with the
most common experience being a cellphone. Thirteen of the
15 participants completed the 6-month follow-up (Fig1).

Table 1: Descriptive statistics of study participant characteristics

Figure 1: CONSORT flow diagram.
Sample size

participants weekly. The coordination of the study was an

For the first and second aims (feasibility and safety), a sample size
of 20 was estimated for this study. This was based on the feasibility

important feature as it was requested by people with PD from
previous work of the authors18. Regarding their health care,
participants from the previous exploratory studies described the

outcome of interest: participation rate. For a sample size of 20, a
participation rate of 80±18% with a 95% confidence interval was
estimated36,37. Based on an estimated 12% dropout rate from the
sample population and type of study35, 88% was assumed as the
actual participation rate for this study. With this in mind and the
sample size justification, 80% power was calculated for this study.
For the third aim (signal of efficacy), using the two-sided paired
Wilcoxon Signed Rank module (PASS v20.0.3; NCSS;
http://wwwncss.com/software/pass)), a sample size of 16 from an

burden of making several appointments with several providers and
not having a single contact person. The authors honored this by
having the study coordinators serve as the main contact to answer
questions, schedule providers, troubleshoot technology problems,
monitor adverse events with participants and providers, and
conduct weekly check-in appointments.
All three parts (speech therapy, physiotherapy, and pharmaceutical
care) of the 8-week telehealth program were administered by

estimated rural PD population of 1000 from both Wyoming and

licensed healthcare providers (four speech-language pathologists,

Nevada would achieve 80% power to detect a mean of paired
differences of 0.4 with an estimated standard deviation of paired
differences of 0.5 and with α=0.05 assuming a normal distribution

two physiotherapists, and two clinical pharmacists) using Zoom
(Table 2). None of the healthcare providers were investigators of
this study and all were blinded to the specific aims of the study. All

of paired differences.

participants received laptop computers equipped with all
necessary software and capabilities to participate in their
telehealth therapy sessions. Participants provided their own
internet access. Participants received the intervention from a single

Coordinated telehealth intervention
This 8-week telehealth program was coordinated by two study
coordinators (one PD nurse and the other an assistant study
coordinator), who both acted as liaisons to the participants and
scheduled all of the treatment sessions and followed up with the

healthcare provider within each of the three parts of the telehealth
program. The coordinated telehealth program required
approximately 8 hours of time from each participant per week of
the 8-week study.

Table 2: Treatment overview for each of the three interventions over the 8-week program

Speech therapy
All speech treatment sessions were consistent with the Lee
Silverman Voice Treatment (LSVT-LOUD®) program38-45.
Participants were sent the laptop computer previously mentioned
with the LSVT Companion software (client version) already
installed. To ensure treatment fidelity, all treating speech-language
pathologists were trained on this regimented treatment protocol
through LSVT® Global and also received online training to deliver
LSVT via telehealth (eLOUD). Additionally, they all used the LSVT
Companion software (clinician version) to conduct the speech
therapy sessions. Participants were also sent a measuring tape and
a microphone to ensure consistent distance and recording fidelity.

week (4 days total)41. The participants were instructed to complete
their home program with the Companion software if possible.
Otherwise, they were asked to practice offline, as this is a standard
aspect of the LSVT treatment.
Physiotherapy
The physiotherapy part of the program was administered by
neurologic physiotherapists who had experience and expertise
treating patients with PD. To ensure treatment fidelity, both
treating physiotherapists were trained by the primary investigator
on the program, which was based on a previously published
program35. Prior to beginning the study, each participant received

The speech therapy program consisted of four 60-minute sessions
per week for the first 4 weeks of the program (Table 2). Session
activities consisted of hierarchical drill and practice exercises
(ranging from sustained phonation of a vowel to reading
paragraphs and participant-directed conversation), focusing on

a pulse oximeter for safety monitoring, a cycling pedal ergometer
for sitting aerobic training, and elastic bands to use for strength
training. Physiotherapists supervised the real time, one-on-one,
60-minute physiotherapy program once per week for the 8 weeks.
Participants were also assigned a participant-specific home
exercise program to complete two additional 60-minute sessions

sustaining intensity/loudness within the participant’s optimal pitch
range. Specific tasks were chosen by the speech-language

per week. As this was a pragmatic study, physiotherapists tailored
the intensity and the modality of the exercise within the study

pathologists to individually tailor this program, based on the type
of communication and communication partners the person with
PD had, as well as the participant’s interests and preferences.
During the second 4 weeks of the program, participants met with
the speech-language pathologist once per week but were also
instructed to complete the LSVT home practice regimen, which
consisted of three additional, non-supervised practice sessions per

parameters (Table 2). This flexibility allowed the physiotherapists to
use their clinical judgement to tailor the exercises to the needs and
capabilities of individual participants and to address the common
motor impairments associated with PD. Because of the telehealth
format, a primary focus of this physiotherapy was safety,
particularly with balance training. All exercises that put the
participant at risk for a fall were conducted with the participant’s

hand at a counter or chair, or in a sitting position when necessary
for safety.
Pharmaceutical care
The pharmaceutical care arm of the intervention was administered
by clinical pharmacists with experience in PD pharmaceutical care.
All medication management sessions were scheduled for up to
60 minutes (ranging from 15 minutes to 60 minutes, depending on
the number of medications taken by the participant and the
number of drug therapy problems identified) per week for the
8-week study (Table 2). Each week, the pharmacist worked with the
participant to identify potential drug therapy problems
(eg unnecessary drug therapy, necessary additional drug therapy,
ineffective drugs, calibrating dosage, adverse drug reactions,
medication adherence). The pharmacist would then make
recommendations to the primary care provider regarding
adjustments if needed46. The pharmaceutical care sessions were
participant-focused and generally covered the Pharmacists’ Patient
Care Process as outlined in the Pharmaceutical Care Practice
model46,47. The three major steps in the Patient Care Process are
the assessment of the patient, his or her medical problems, and
drug therapies leading to drug therapy problem identification; care
plan development; and follow-up evaluations.
Outcome measures

scale for the following eight different dimensions: mobility,
activities of daily living, emotional wellbeing, stigma, social
support, cognitions, communication, and bodily discomfort. Each
of the 39 items ranges from 0 (‘never’) to 4 (‘always’). The overall
score and subsection scores are calculated by taking the means of
each item divided by the total for that section, thus converting the
score into a percentage, with higher percentages equating to more
disability.
Speech therapy To determine the signal of efficacy for speech
therapy, the Communicative Effectiveness Survey (CES)49-51 was
used. It is a self-report rating scale designed to measure
communication effectiveness in various life situations. The CES is
an eight-question scale using a four-point Likert scale (1=’not at all
effective’; 4=’very effective’) on how the participant’s social
participation is affected by their speech and communication. The
scores range from 8 (‘not effective’) to 32 (‘very effective’). For
acoustic data outcomes, vocal sound level intensity was assessed
using the LSVT Companion software. To acquire acoustic data,
participants were asked to perform a prolonged vowel phonation
(‘ah’) at least 10 times, as loudly as possible within quality
parameters for as long as possible. The average sound pressure
level (dB SPL) and duration for each try was then averaged across
the 10 or more tries. From these two measurements, a third
outcome, ‘work’, was derived by multiplying the average SPL by

Outcomes for first aim (feasibility) and second aim
(safety): The main outcome of the first aim was the number of

the average duration. These data were collected by the treating
speech-language pathologists via the clinician version of the LSVT
Companion software.

sessions completed by each participant. Feasibility was based on
clinical experience and research in the same population by the

Physiotherapy For a signal of efficacy in the physiotherapy

35

research team ; it was assessed using attendance and attrition or
dropout rate during the 8-week intervention and satisfaction
(dichotomous (yes or no) about whether they felt the intervention
was useful and helpful) at the 6-month point. Dropouts were
operationally defined as those who stopped coming to treatment
sessions and/or did not complete the 8-week measurement point.
Based on previous research, less than 15% attrition was considered
feasible35. For satisfaction, the threshold for feasibility was 90%. To
be considered ‘feasible’, the threshold was that 80% of participants
would have attended at least 80% of the treatment sessions over
the 8-week trial. To collect these data, the study coordinators
contacted participants weekly to determine the numbers of
sessions completed. In addition, the study coordinators recorded
the frequency and nature of adverse events during the 8 weeks of
the program (second aim).
Outcomes for second aim (signal of efficacy): A signal of
efficacy for the 8-week telehealth program would be determined if
there was a positive trend toward improvement across the
outcome variables below. Data for signal of efficacy were collected
before and immediately after the program in the ‘on’ PD
medication state in the following domains.
Overall outcome – disease-specific quality of life For an overall
assessment of the program, quality of life was assessed using a
disease-specific questionnaire, the PD Questionnaire-39
(PDQ-39)48. The PDQ-39 is a 39-item self-report quality-of-life

domain, one performance-based measure was collected by the
treating physical therapists, 30 second Sit-To-Stand (30STS) test52.
The 30STS test measures how many times the participant can
stand from sitting in 30 seconds. In addition, data from the
Parkinson’s Fatigue Scale53, a measurement of disease-specific
fatigue, was collected by the nurse study coordinator. This scale
measures 16 items using a five-point Likert scale for each item.
Scores are averaged and range from with a low score of 1 (‘low
fatigue’) and a high score of five (‘high fatigue’). To assess diseasespecific motor function, the clinician-scored Movement Disorder
Society Unified PD Rating Scale Part III (MDS-UPDRS III)54-58 was
collected by the nurse study coordinator, who had been trained to
administer the scale and who had administered the scale hundreds
of times over many years of PD clinical practice. The MDS-UPDRS
III has 18 items with scores ranging from 0 (‘normal’) to 4 (‘severe’).
Two items that could not be assessed using telehealth were
removed (items 3.3 (rigidity) and 3.12 (postural instability)). Thus,
16 of the 18 items were scored. A score of 0 indicates normal
function whereas a score of 64 (the highest possible score) is
suggestive of severe motor deficits.
Pharmaceutical care The main outcome for the pharmaceutical
care intervention was adherence, measured through the gold
standard of pill count, as described elsewhere59-64. This outcome
was measured by the nurse study coordinator and consisted of
percentage adherence to the prescribed PD medications.

Data analysis

Ethics approval

Data were analyzed using SAS software v9.4 (SAS Institute,

Participants consented under University of Wyoming Institutional

http://www.sas.com) and α=0.05. For the first aim (feasibility) and
second aim (safety), the number of completed sessions, dropouts,
and the number of participant-reported adverse events were
tabulated. Participant satisfaction was tabulated from the

Review Board approval (Protocol #20171030MH01724).

dichotomous response (‘yes’ or ‘no’) about whether the
coordinated program was useful or helpful to them. For the third
aim (signal of efficacy), because of the small sample size the data
were analyzed with non-parametric, within-group comparisons
using Wilcoxon Signed Rank tests for each of the aforementioned
pre and post outcomes. Cohen’s D ((meanpre – meanpost)/standard
deviationdifference) for the pre and post difference was used to
determine effect sizes for each outcome. For the 6-month

Results
Feasibility
For feasibility, there were no dropouts over the 8-week
intervention. However, at the 6-month follow-up, the research
team was unable to contact 2 of the 15 participants. All
15 participants of the 8-week intervention completed more than
80% of their scheduled treatment sessions (Table 3). At the
6-month follow-up, all 13 participants were satisfied with the
intervention and deemed the study as useful or helpful to them.

outcomes, the Wilcoxon Signed Rank Test was also utilized.
Table 3: Session attendance for different intervention components of the study

Safety
There were no serious adverse effects for any of the speech
therapy, physiotherapy, or pharmaceutical care treatment over the
duration of the study. For speech therapy, eight participants
reported nine instances of adverse events (six hoarse voice, one
sore throat, one strained neck, one coughing more than usual).
However, the treating speech therapists only noted three
participants with one adverse event each (dry mouth, voice
cracking a lot, and extreme vocal fatigue). For physiotherapy, two
participants reported two adverse events (strain/sprain and muscle
soreness), both of which resolved without any intervention. The
treating physical therapists did not report any adverse events. For
pharmaceutical care, there were no medication-related adverse
events. Of all of the treatment sessions conducted for all of the
participants, there was a participant self-report of an adverse event
in only 0.9% of the sessions.
Signal of efficacy
Outcomes across the four domains (quality of life, speech therapy,

physiotherapy, and pharmaceutical care) are presented in Table 4.
Effect sizes for those variables are detailed in Figure 2. Based on
Wilcoxon Signed Rank Test results, the two outcomes that were
statistically significant from pre to post were the 30STS (p=0.0039)
and acoustic work (ie intensity times duration, p=0.0309; medians
and interquartile ranges (IQR) are in Table 4). Because the
telehealth LSVT-LOUD training stopped after 4 weeks and
transitioned to a home program, interim analyses of the outcomes
from pre to the 4-week measurements were conducted for the
acoustic data: median volume changed from 78.7 dB (IQR=4.9) to
80.1 dB (IQR=7.6) (p=0.2011), median duration changed from 9.9 s
(IQR=2.8) to 11.5 s (IQR=5.3) (p=0.0214), and acoustic work
changed from 756.0 dB.s (IQR=198.4) to 876.3 dB.s (IQR=455.5)
(p=0.0089) (Table 4). At baseline, 2 of 15 participants were more
than 80% adherent to their PD medications. Although the
pharmacists reported that all participants were adherent to their
PD medications for the duration of the 8-week study, after the
intervention only 4 of 15 were more than 80% adherent to their PD
medications.

Table 4: Means and medians for each outcome variable associated with quality of life, speech therapy, and physiotherapy†

Figure 2: Effect sizes (Cohen’s D for paired measures65)† for the pre and post scores for the 8-week intervention.
6-month follow-up
There was no evidence of statistically significant changes from the
8-week measurement to the 6-month follow-up for any of the
outcome measurements.
Discussion

study in this area. Attendance at the required sessions was
excellent for all participants and there were no dropouts over the
8-week program. Participants attended 96% of the scheduled
speech therapy sessions, 93% of the scheduled physiotherapy
sessions, and 85% of the scheduled pharmaceutical care sessions.
There were no dropouts during the study and all who were
interviewed at the 6-month follow-up were satisfied with the

Results of this exploratory pilot study suggest that an 8-week
coordinated telehealth program, consisting of speech therapy,
physiotherapy, and pharmaceutical care, was both feasible and

program. Collectively, these feasibility results are consistent with
the feasibility reported in other telemedicine management
programs12,14, telehealth exercise programs66-69, telerehabilitation

safe for people with PD living in rural areas. Additionally, there was
a signal of efficacy that this telehealth program may be associated
with changes that favor improvement across a majority of the
outcome variables. However, due to the design of the study,
causative inference due to the intervention should be cautioned.
Future research using a more rigorous and controlled design of

balance training programs70, and LSVT speech therapy71-75 for
people with PD. Although all of these studies reported the
feasibility of telehealth for people with PD, they were all
monodisciplinary studies and not multidisciplinary like the present
study. Thus, the results of the present study are the first, to the
authors’ knowledge, to offer preliminary evidence that a

this promising telehealth program for people with PD in rural areas
is warranted.

coordinated, multidisciplinary approach is feasible in PD.

Although there were technology challenges with the intervention
(detailed in the limitations section), the feasibility of this
coordinated program was sufficient enough to warrant continued

without any medical attention. Moreover, all of them are
considered Grade 1 adverse events (Common Terminology Criteria
for Adverse Events), which are the most minor adverse events in

All of the adverse events in this study were minor and resolved

the spectrum76. Importantly, these minor adverse events were
consistent with the frequency and types of minor adverse events
that are experienced in typical in-person rehabilitation programs.

improving patient care and experience – decreasing travel

Importantly, there were no falls, which was the biggest a priori
concern for the physiotherapy portion of the program. Both of the
physiotherapy adverse events are similar to the types of minor
adverse events that happen with physiotherapy and exercise

care for people with PD in rural areas

programs77,78. The speech therapy adverse events are consistent
with the frequency and type of minor adverse events expected
with in-person LSVT-LOUD therapy38,79. Another primary concern
of the research team was mitigating the possibility of a serious
adverse event that would necessitate immediate medical care,
because the participants were living in rural areas and would not
likely have immediate access to emergency care services. Thus, the
exclusion criteria were more extensive than those for a typical inperson research study, and this would certainly limit the
generalizability. Additionally, the exercises in the physiotherapy
portion were lower in intensity than what would typically be
experienced in an in-person physiotherapy session. As there was
no spotter, balance training tasks were not as challenging as would
be experienced in an in-person physiotherapy session.
An important part of this pilot study was determining if there was
a signal of efficacy for this intervention to determine if future
research in this area was warranted. While there were only two
statistically significant improvements among the 16 outcome
variables, 14 of the 16 outcomes had small to medium effect sizes
(Fig2). Collectively, these data suggest a signal of efficacy that

time and increasing accessibility to PD specialists
improving population health – integrating and optimizing
reducing healthcare costs – using technology that reduces
outpatient visits and allows access to experts who can
proactively manage issues early for those living in rural
areas3.
Limitations
One of the strengths of the present study is that this was a
program involving an integrated coordination of multidisciplinary
care for people with PD living in rural areas without access to PD
specialists. However, the typical PD care team clearly involves other
disciplines (eg occupational therapist, nutritionist, movement
disorders neurologist, psychologist, social worker) that were not
included in this study. Future coordinated, multidisciplinary
telehealth approaches for people with PD should consider
integrating other important PD care team members, as has been
described in the literature3,88. Another limitation of the present
study is that enrollment targets were not met within the
recruitment and funding window. Subsequently, each of the aims
were likely underpowered and, therefore, the results and
generalizability of the findings should be interpreted with some
caution. Additionally, since ‘commitment to attend scheduled
sessions’ was intended to create a more committed participant
pool, it may have unintentionally contributed to a biased sample

warrants further investigation. In addition, these signal of efficacy
results are consistent with the ‘in-person’ efficacy reported in

and, therefore, limit the generalizability to those willing to
participate in a trial like this.

systematic reviews and meta-analyses for speech language
therapy80,81, LSVT-LOUD81,82, physiotherapy77,83, and

While an extended discussion of the technology challenges would

exercise77,84-86 for people with PD. It should be noted that the
meta-analysis by Yuan et al for LSVT-LOUD did not find a
difference in therapeutic effect between in-person and online
LSVT, which supports the notion that these programs are
comparable82. Additionally, a recent meta-analysis in PD found
that telehealth is effective at improving motor impairment in PD,
which is also consistent with the findings of this study87.
Collectively, there is considerable evidence for each of the
interventions used in the present study in an in-person
monodisciplinary approach. The uniqueness of the present study is
that it was not only conducted using a telehealth format but was
also multidisciplinary and focused on coordinated care. This study
provides preliminary evidence that the foundational, in-person
therapeutic efficacy of the different intervention components in
this study is potentially transferrable to a telehealth format. If this
were to hold true in larger scale trials, then it would be potentially
meaningful and impactful in helping address each of the aims in
the Triple Aim to improve the US healthcare system23. The Triple
Aim as applied to the present study includes:

not be appropriate here, it should be noted that there were some
logistical and technology related challenges (eg audio/video
problems, slow internet connections, participant
inexperience/intimidation by laptops/telehealth technology, laptop
rebooting/updates during telehealth sessions). These types of
challenge were expected, and effort was made to mitigate them;
however, they remained a primary issue over the duration of the
study. While all participants were tested in the ‘on’ PD medication
phase, there was a lack of control of assessment occurring at the
peak ‘on’ phase times and this may have impacted performance
with the outcome variables. Another limitation was that, although
home exercise program adherence was tracked and encouraged
by the treating speech and physical therapists, it was not formally
tracked for reporting purposes. Lastly, the pill count data was
taken by the nurse study coordinator rather than by a pharmacist,
and this resulted in some inconsistencies, which precluded a more
detailed report of participant medication adherence. In light of this
and other confounding factors related to changing medication
regimens over the duration of the study, it is recommended that
future research in a coordinated, multidisciplinary study like this
utilize a medication management run-in design, wherein
medication management is the first phase and, once the PD
medications have been sufficiently stabilized, the rest of the
coordinated intervention is implemented.

Conclusion
An 8-week coordinated telehealth program, consisting of speech
therapy, physiotherapy, and pharmaceutical care, was both feasible
and safe for people with PD living in rural communities.
Additionally, results from this pilot study suggest that there was a

signal of efficacy favoring improvement across a majority of the
outcomes for this telehealth program. However, because this was a
single cohort design, causal inference should be cautiously
interpreted. Future research using a more rigorous and controlled
design of this coordinated telehealth program for people with PD
in rural areas is warranted.
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